Alere, Inc., Bio-Rad Laboratories and Thermo Fisher Scientific, Inc. are Dominating the Market for Global Anti-Nuclear Antibody Test Market In 2017

Global Anti-Nuclear Antibody Test Market is expected to reach USD 1,964.47 million by 2025 from USD 1,093.40 million in 2017, at a CAGR of 7.7% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Global Anti-Nuclear Antibody Test MarketAccess Full Report:

The global anti-nuclear antibody test market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. In 2017, the global anti-nuclear antibody test market is dominated by Alere, Inc., followed by Bio-Rad Laboratories and Thermo Fisher Scientific, Inc. Other players in this market include are Trinity Biotech, Antibodies Inc., EUROIMMUN AG, and Immuno Concepts among others.


Founded in 2001 and headquartered in Massachusetts, U.S. Alere Inc. operates in rapid diagnostics tests devices. Alere segments are focused on cardiometabolic, infectious disease, and toxicology testing. Alere Inc. offers wide range of diagnostic tests for cardiometabolic disease, and toxicology in the United States and across the globe. The products offered by the company includes rapid diagnostic test systems for diagnosis of point-of-care analyzers and test cassette systems for the blood cholesterol, glucose, and related lipids tests and over-the-counter tests for cholesterol monitoring; blood analysis systems for blood gas, electrolyte, and metabolite testing. The anti-nuclear antibody test products are offered by the test and instruments categories.

Abbott Laboratories acquired Alere which has significantly expanded Abbott's global diagnostics presence. Alere is operating as a subsidiary of Abbott Laboratories.


Bio-Rad Laboratories, Inc. founded in 1952 and headquartered in California, U.S. It is engaged in development and production of specialty chemicals used in biochemical, pharmaceutical and other life science research applications. It operates its business through its two business segments life science and clinical diagnostics.

Life Science segment offers the wide range of instruments, software, consumables, reagents, and content for the growing fields of cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education.

Clinical Diagnostics offers the wide range of innovative products to clinical laboratories worldwide. It has its global presence in over 35 countries.


Thermo Fisher Scientific Inc. founded in 1956 and headquartered at Massachusetts, U.S. The company operates its business through four segments namely, laboratory products & services, life sciences & solutions, analytical instruments & speciality diagnostic. Life sciences solutions provides an extensive portfolio of instruments, reagents and consumables used in medical research and biological, discovery and production of vaccines and new drugs as well as diagnosis of diseases. Analytical instruments segment provides a broad offering of consumables, instruments, software and services that are used for a range of applications in the laboratory, on the production line and in the field. Specialty diagnostics segment provides a wide range of diagnostic test kits, reagents, instruments and associated products used to increase the speed and accuracy of diagnosis.

The products for anti-nuclear antibody test are offered by the product category named antibodies & immunoassays.

Thermo Fisher Scientific Inc. has operating companies across the United States, Europe, Western Hemisphere, Africa, and Asia-Pacific. Some of its subsidiaries includes Thermo Electron Australia Pty Limited (Australia), Thermo Electron Holdings SAS (France), Thermo Finland Holdings LLC (Delaware), Kendro Laboratory Products (H.K.) Limited (Hong kong), Niton Europe GmbH (Germany), Thermo Ramsey S.A.(Spain) etc.c